Skip to main content
. Author manuscript; available in PMC: 2017 Apr 14.
Published in final edited form as: J Mater Chem B. 2016 Mar 3;4(14):2428–2434. doi: 10.1039/C5TB02172C

Figure 5.

Figure 5

Biodistribution of radiolabeled nanocarriers in the blood, lung, kidney, spleen, liver, thyroid, and brain over time reported as % ID (n=3). Decreasing radioactivity in the blood and increasing radioactivity in the liver and spleen over time is consistent with gradual RES clearance of nanocarriers and prolonged systemic circulation. Decreasing radioactivity in the kidney suggests minimal renal clearance. Low lung radioactivity suggests that there is no specific binding despite the high blood perfusion level. Low thyroid radioactivity suggests that 125I did not leach from nanocarrier core.